Oncology drugs market seen reaching $763.21B by 2035

Market Research Future projects the global oncology drugs market will grow from $202.26 billion in 2025 to $763.21 billion by 2035, powered by rising cancer cases, precision medicine, targeted therapies and immunotherapy. North America remains the largest regional market, while oral drugs, breast cancer and adult patients lead current demand.

Why it matters: - The oncology drugs market is on track for rapid expansion as cancer prevalence rises and treatment shifts toward more precise, less toxic therapies. - The projected jump to $763.21 billion by 2035 points to sustained demand for targeted drugs, immunotherapy and biomarker-guided care. - The market growth also reflects broader pressure on health systems to improve survival rates and patient quality of life.

What happened: - Market Research Future projected the global oncology drugs market will rise from $202.26 billion in 2025 to $763.21 billion by 2035. - The forecast implies a 14.20% compound annual growth rate over the 2025-2035 period. - The market base was estimated at $177.1 billion in 2024. - The report said rising cancer prevalence, precision medicine advances, biomarker diagnostics and combination treatment strategies are the main growth drivers. - The report identified North America as the largest regional market, with Europe second and Asia-Pacific as the fastest-growing major region.

The details: - The World Health Organization reported nearly 20 million new cancer cases and about 9.7 million deaths globally in 2022. - WHO projections show more than 35 million new cancer cases by 2050. - IHME estimated global cancer cases have increased by more than 65% over the past two decades. - IHME also said cancer causes more than 10 million deaths annually. - Roche generated over CHF 18 billion in oncology revenue. - Bristol-Myers Squibb reported oncology revenue above $17 billion. - Merck & Co. recorded oncology sales above $29 billion. - The report said chemotherapy was the largest drug category in 2024 with a 38% share. - Targeted therapy was the fastest-growing drug type. - Immunotherapy was also gaining traction as a major treatment class. - Hormonal therapy remained a specialized segment for cancers such as breast and prostate cancer. - Breast cancer was the largest therapeutic area in 2024 with a 26% share. - Lung cancer was the fastest-growing indication. - Oral drugs held a 44% share in 2024, making them the dominant route of administration. - Intravenous delivery was the fastest-growing administration route. - Adult patients made up 72% of the market in 2024. - Pediatric oncology was the fastest-growing demographic segment. - North America generated about $79.70 billion in 2024 and held more than 45% of global revenue. - Europe was valued at $53.13 billion in 2024 and accounted for a 30% share. - Asia-Pacific represented about 20% of the global market. - The Middle East and Africa held about 5% of the global share. - Gilead Sciences said its oncology revenue surpassed $2 billion annually. - Novartis acquired a biotechnology firm focused on cancer treatments in June 2023.

Between the lines: - The market data shows oncology is becoming more segmented, with demand shifting toward therapies matched to specific biomarkers and cancer subtypes. - Large drugmakers are using revenue from established oncology portfolios to fund new combinations, cell therapies and precision-medicine programs. - The regional split suggests the U.S. and Europe remain innovation centers, while Asia-Pacific offers the strongest growth runway. - The report’s emphasis on telehealth, AI drug discovery and combination therapy research signals where investment may flow next.

What's next: - The report expects continued growth through 2035 as cancer incidence rises and treatment adoption widens. - New opportunities may emerge in telehealth for oncology consultations, AI-driven drug discovery and combination therapy research. - Regulatory approvals, expanded screening and broader biomarker testing are likely to shape the next phase of market growth. - More information is available in the market sample request and the full report.